No Data
The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."
In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.
Invested approximately 12.09 million to repurchase 0.39 million shares! Gushengtang has repurchased Stocks 41 times over the past 6 months, demonstrating confidence and commitment to development.
On December 18, 2024, Guoshengtang announced its next disclosure report, revealing that the company had once again taken action, spending approximately 12.09 million HKD to repurchase and cancel 0.39 million shares. It is worth mentioning that this repurchase marks the 41st stock buyback action by Guoshengtang in the past six months, demonstrating its continued activity and strategic layout in the Capital Markets. In fact, from June 20, 2024, to date, Guoshengtang Holdings Limited has spent nearly 0.13 billion HKD to repurchase about 3.53 million shares of the company. The stable advancement of the Share Buyback plan not only shows Guoshengtang's commitment.
Gushengtang (02273.HK) spent 5.32 million Hong Kong dollars to repurchase 0.1687 million shares on December 16.
Gelonghui reported on December 16 that Gushengtang (02273.HK) announced it spent HKD 5.32 million on December 16 to repurchase 0.1687 million shares.
HAITONG SEC: The trend of moderate price reductions in the centralized procurement of Traditional Chinese Medicine varieties continues, and the domestic Pharmaceutical industry is expected to usher in a wave of mergers and acquisitions.
HAITONG SEC released a Research Report stating that the gentle trend of price reduction for Traditional Chinese Medicine varieties continues.
Is There Now An Opportunity In Gushengtang Holdings Limited (HKG:2273)?
Gu Shengtang's Tu Zhi Liang: AI-assisted diagnosis and treatment + internet plus-related hospital + innovative chinese patent medicine, three-pronged approach to help traditional Chinese medicine reach the world.
Recently, Tu Zhiliang, the founder and chairman of Gushengtang, was successfully selected as one of the "2024 Forbes China's Top 100 Most Influential Chinese Elite". The official Forbes account published a special interview with Mr. Tu Zhiliang in the headline position. The full text is as follows: From establishing Gushengtang in 2010 to ringing the bell at the Hong Kong Stock Exchange in 2021, Tu Zhiliang has shown a breakthrough path for the entire traditional Chinese medicine industry. As the "first stock of Chinese medicine medical services", the success of Gushengtang has not only promoted the modernization and international development of traditional Chinese medicine, but also helped the entire Chinese medicine industry achieve an important "transformation". Looking back on this entrepreneurial experience, Tu Zhiliang said, "At the beginning...
Investors Give Zhejiang Crystal-Optech Co., Ltd (SZSE:002273) Shares A 27% Hiding
